Lupus Science & Medicine: 5 (1)

Animal models

Accelerated model of lupus autoimmunity and vasculopathy driven by toll-like receptor 7/9 imbalance (14 May, 2018)
Yudong Liu, Nickie L Seto, Carmelo Carmona-Rivera, Mariana J Kaplan

Brief communication

Cytoplasmic FOXO1 identifies a novel disease-activity associated B cell phenotype in SLE (24 October, 2018)
Molly K Hritzo Ahye, Amit Golding
QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus (13 August, 2018)
Nicola Edwards, Alexander W W Langford-Smith, Benjamin J Parker, Ian N Bruce, John A Reynolds, M Yvonne Alexander, Eoghan M McCarthy, Fiona L Wilkinson
Associations between type I interferon and antiphospholipid antibody status differ between ancestral backgrounds (13 January, 2018)
Taro Iwamoto, Jessica Dorschner, Meenakshi Jolly, Xiangyang Huang, Timothy B Niewold

Biomarker studies

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE (22 November, 2018)
Kerry A Casey, Xiang Guo, Michael A Smith, Shiliang Wang, Dominic Sinibaldi, Miguel A Sanjuan, Liangwei Wang, Gabor G Illei, Wendy I White
Similar dysregulation of lupus-associated miRNAs in peripheral blood mononuclear cells and splenic lymphocytes in MRL/lpr mice (5 November, 2018)
Zhuang Wang, Bettina Heid, Rujuan Dai, Sattar Ansar Ahmed
Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus (19 October, 2018)
Fabien B Vincent, Laura Slavin, Alberta Y Hoi, Arthur Richard Kitching, Fabienne Mackay, James Harris, Rangi Kandane-Rathnayake, Eric F Morand
Elevation of serum anti–glucose-regulated protein 78 antibodies in neuropsychiatric systemic lupus erythematosus (10 October, 2018)
Yu Matsueda, Yoshiyuki Arinuma, Tatsuo Nagai, Shunsei Hirohata
Measuring lupus arthritis activity using contrasted high-field MRI. Associations with clinical measures of disease activity and novel patterns of disease (26 July, 2018)
Eric S Zollars, Madison Hyer, Bethany Wolf, Russell Chapin
TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus (4 June, 2018)
Helena Idborg, Susanna Eketjäll, Susanne Pettersson, Johanna T Gustafsson, Agneta Zickert, Marika Kvarnström, Vilija Oke, Per-Johan Jakobsson, Iva Gunnarsson, Elisabet Svenungsson
Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE (23 May, 2018)
Joan T Merrill, Michelle A Petri, Jill Buyon, Rosalind Ramsey-Goldman, Kenneth Kalunian, Chaim Putterman, John Conklin, Richard A Furie, Thierry Dervieux

Childhood lupus

Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus (17 November, 2018)
Ashwaq AlE'ed, Pinar Ozge Avar Aydin, Nora Al Mutairi, Alhanouf AlSaleem, Hafize Emine Sonmez, Michael Henrickson, Jennifer L Huggins, Seza Ozen, Sulaiman M Al-Mayouf, Hermine I Brunner
Analysis of relationships between 25-hydroxyvitamin D, parathyroid hormone and cathelicidin with inflammation and cardiovascular risk in subjects with paediatric systemic lupus erythematosus: an Atherosclerosis Prevention in Paediatric Lupus Erythematosus (APPLE) study (15 June, 2018)
Varsha Gupta, Vin Tangpricha, Eric Yow, Grace A McComsey, Laura Schanberg, Angela Byun Robinson

Clinical trials and drug discovery

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus (26 November, 2018)
Joan T Merrill, Richard Furie, Victoria P Werth, Munther Khamashta, Jorn Drappa, Liangwei Wang, Gabor Illei, Raj Tummala
Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study (26 November, 2018)
Ronald F van Vollenhoven, William Stohl, Richard A Furie, Norma Lynn Fox, James G Groark, Damon Bass, Milena Kurtinecz, Bonnie F Pobiner, William J Eastman, Tania Gonzalez‑Rivera, David Gordon
Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials (6 August, 2018)
Mimi Kim, Joan T Merrill, Kenneth Kalunian, Leslie Hanrahan, Peter Izmirly
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus (5 April, 2018)
Jeffrey M Riggs, Richard N Hanna, Bhargavi Rajan, Kamelia Zerrouki, Jodi L Karnell, Divya Sagar, Inna Vainshtein, Erika Farmer, Kimberly Rosenthal, Chris Morehouse, Melissa de los Reyes, Kevin Schifferli, Meina Liang, Miguel A Sanjuan, Gary P Sims, Roland Kolbeck
Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers (23 March, 2018)
Raj Tummala, Tomas Rouse, Anna Berglind, Linda Santiago
Risk of adverse events from different drugs for SLE: a systematic review and network meta-analysis (9 March, 2018)
Jingru Tian, Yien Luo, Haijing Wu, Hai Long, Ming Zhao, Qianjin Lu

Co-morbidities

Antibodies to Chlamydia trachomatis and reproductive health issues in women with SLE: a case–control study
(21 November, 2018)
Alba Santos, Gilbert Greub, Sébastien Aeby, Dorothea Wunder, Giuseppe Pantaleo, Camillo Ribi
Myocarditis in systemic lupus erythematosus diagnosed by ¹⁸F-fluorodeoxyglucose positron emission tomography
(12 July, 2018)
Alexandra Perel-Winkler, Sabahat Bokhari, Thania Perez-Recio, Afshin Zartoshti, Anca Askanase, Laura Geraldino-Pardilla

Dialogue

Dialogue: commentary on ‘Engaging African-ancestry participants in systemic lupus erythematosus clinic trials’ (17 December, 2018)
Ellen M Ginzler

Epidemiology and outcomes

Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors (17 November, 2018)
Sahena Haque, Sarah Skeoch, Chadi Rakieh, Helena Edlin, Yasmeen Ahmad, Pauline Ho, Rachel Gorodkin, M Yvonne Alexander, Ian N Bruce
Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres (2 November, 2018)
Chiara Tani, Elena Elefante, Miguel Martin-Cascón, Meriem Belhocine, Cristina Lavilla Olleros, Roberta Vagelli, Chiara Stagnaro, Nathalie Costedoat-Chalumeau, Guillermo Ruiz-Irastorza, Marta Mosca
Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort (2 November, 2018)
Ioanna Giannakou, Katerina Chatzidionysiou, Laurence S Magder, Noemi Györi, Ronald van Vollenhoven, Michelle A Petri
Immunosuppressant use and hospitalisations in adult patients with systemic lupus erythematosus admitted to a tertiary academic medical centre (4 June, 2018)
Christine Anastasiou, Olivia Dulai, Amrutha Baskaran, James Proudfoot, Samuel Verhaegen, Kenneth Kalunian
Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort (14 May, 2018)
Julie E Davidson, Qinggong Fu, Sapna Rao, Laurence S Magder, Michelle Petri
Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus (27 February, 2018)
Joseph M Kheir, Carla J Guthridge, Jonathon R Johnston, Lucas J Adams, Astrid Rasmussen, Timothy F Gross, Melissa E Munroe, Rebecka L Bourn, Kathy L Sivils, Joel M Guthridge, Michael H Weisman, Daniel J Wallace, Juan-Manuel Anaya, Adriana Rojas Villarraga, James N Jarvis, John B Harley, Judith A James
Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort (27 February, 2018)
Chiara Tani, Roberta Vagelli, Chiara Stagnaro, Linda Carli, Marta Mosca

Lupus nephritis

Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis (4 September, 2018)
Vinicius Domingues, Benjamin A Levinson, Nicole Bornkamp, Judith D Goldberg, Jill Buyon, H Michael Belmont

Immunology and inflammation

Increased alloreactive and autoreactive antihuman leucocyte antigen antibodies associated with systemic lupus erythematosus and rheumatoid arthritis (25 September, 2018)
Rachael P Jackman, Giovanna I Cruz, Joanne Nititham, Darrell J Triulzi, Lisa F Barcellos, Lindsey A Criswell, Philip J Norris, Michael P Busch
Kynurenine pathway is altered in patients with SLE and associated with severe fatigue (23 May, 2018)
Karolina Åkesson, Susanne Pettersson, Sara Ståhl, Izabella Surowiec, Mattias Hedenström, Susanna Eketjäll, Johan Trygg, Per-Johan Jakobsson, Iva Gunnarsson, Elisabet Svenungsson, Helena Idborg

Review

Engaging African ancestry participants in SLE clinical trials (11 December, 2018)
Aderike Anjorin, Peter Lipsky
Alopecias in lupus erythematosus (25 October, 2018)
Josef Symon Salgado Concha, Victoria P Werth
Obstetric antiphospholipid syndrome (25 September, 2018)
Aleksandra Antovic, Maria Sennström, Katarina Bremme, Elisabet Svenungsson
Patient-reported outcome measures for use in clinical trials of SLE: a review (21 August, 2018)
Zara Izadi, Julie Gandrup, Patricia P Katz, Jinoos Yazdany
Transition and transfer of the patient with paediatric-onset lupus: a practical approach for paediatric and adult rheumatology practices (13 August, 2018)
Rebecca E Sadun, Laura E Schanberg
DNA methylation 101: what is important to know about DNA methylation and its role in SLE risk and disease heterogeneity (25 July, 2018)
Cristina M Lanata, Sharon A Chung, Lindsey A Criswell
Lupus community panel proposals for optimising clinical trials: 2018 (23 March, 2018)
Joan T Merrill, Susan Manzi, Cynthia Aranow, Anca Askenase, Ian Bruce, Eliza Chakravarty, Ben Chong, Karen Costenbader, Maria Dall’Era, Ellen Ginzler, Leslie Hanrahan, Ken Kalunian, Joseph Merola, Sandra Raymond, Brad Rovin, Amit Saxena, Victoria P Werth
Mouse models of lupus: what they tell us and what they don’t (21 January, 2018)
Mara Lennard Richard, Gary Gilkeson
Very delayed lupus nephritis: a report of three cases and literature review (12 January, 2018)
André R Alexandre, Pedro L Carreira, David A Isenberg

Meeting report

Report of the inaugural Interferon Research Summit: interferon in inflammatory diseases (15 June, 2018)
Mary K Crow, Lars Rönnblom

Correction

Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
(22 December, 2018)
Correction: Patient-reported outcome measures for use in clinical trials of SLE: a review
(10 October, 2018)
Correction: Report of the inaugural Interferon Research Summit: interferon in inflammatory diseases
(4 September, 2018)
Correction: Dysregulation of miRNAs expression levels and disease activity in SLE patients
(25 July, 2018)
Correction: Lupus community panel proposals for optimising clinical trials: 2018
(11 June, 2018)

Thank you to our reviewers

Thank you to our reviewers 2017 (28 March, 2018)

Main menu

Table of contents

2018 - Volume 5 - 1

Animal models

Brief communication

Biomarker studies

Childhood lupus

Clinical trials and drug discovery

Co-morbidities

Dialogue

Epidemiology and outcomes

Lupus nephritis

Immunology and inflammation

Review

Meeting report

Correction

Thank you to our reviewers

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

2018 - Volume 5 - 1

Animal models

Brief communication

Biomarker studies

Childhood lupus

Clinical trials and drug discovery

Co-morbidities

Dialogue

Epidemiology and outcomes

Lupus nephritis

Immunology and inflammation

Review

Meeting report

Correction

Thank you to our reviewers